+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atopic dermatitis Global Clinical Trials Review, H2, 2019

  • ID: 4629774
  • Clinical Trials
  • December 2019
  • Region: Global
  • 716 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Bayer AG
  • Eli Lilly and Co
  • Galderma SA
  • GlaxoSmithKline Plc
  • LEO Foundation
  • MORE
Atopic dermatitis Global Clinical Trials Review, H2, 2019

Summary

The clinical trial report, “Atopic dermatitis Global Clinical Trials Review, H2, 2019“ provides an overview of topic dermatitis clinical trials scenario. This report provides top line data relating to the clinical trials on topic dermatitis . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Bayer AG
  • Eli Lilly and Co
  • Galderma SA
  • GlaxoSmithKline Plc
  • LEO Foundation
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Atopic Dermatitis (Atopic Eczema)
  • Nov 14, 2019: Dermira presents new scientific research findings from the lebrikizumab program at Leading International Itch Conference
  • Nov 12, 2019: XBiotech announces first patient enrolled in placebo-controlled clinical study evaluating its anti-IL-1 therapy Bermekimab in patients with Atopic Dermatitis (Eczema)
  • Nov 10, 2019: Nektar Therapeutics presents data from first-in-human phase 1a study on novel T regulatory cell stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
  • Nov 08, 2019: AnaptysBio reports Etokimab ATLAS phase 2b clinical trial in moderate-to-severe atopic dermatitis fails to meet primary endpoint
  • Nov 06, 2019: Arena Pharmaceuticals presented new data highlighting the human mass balance and metabolism profile of Etrasimod at AAPS
  • Nov 04, 2019: Ichnos Sciences provides update on its Atopic Dermatitis drug candidate ISB 830
  • Nov 04, 2019: Ichnos Sciences announces completion of enrollment of phase 2b trial for Investigational Therapy - ISB 830
  • Oct 28, 2019: MorphoSys: MOR106 clinical development in atopic dermatitis stopped
  • Oct 28, 2019: Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
  • Oct 23, 2019: RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193
  • Oct 23, 2019: BTX 1503 acne phase 2 study results presentation
  • Oct 23, 2019: AnaptysBio: Promising therapy for common form of eczema identified in early-stage trial
  • Oct 22, 2019: ASLAN Pharmaceuticals enrolls first patient in proof-of-concept study for ASLAN004 targeting Atopic Dermatitis
  • Oct 17, 2019: Dermira presents data from phase 2b study of Lebrikizumab in patients with Atopic Dermatitis at Fall Clinical Dermatology Conference
  • Oct 14, 2019: Pfizer’s JAK1 inhibitor performs well in atopic dermatitis
  • Oct 10, 2019: Dermira launches Phase III lebrikizumab programme
  • Oct 10, 2019: Dermira to present data from phase 2b study of Lebrikizumab in patients with atopic dermatitis at Fall Clinical Dermatology Conference
  • Oct 10, 2019: Galderma advances phase 3 clinical study with Nemolizumab in moderate-to-severe atopic dermatitis
  • Oct 09, 2019: AbbVie announces new data from Upadacitinib at the 28th European Academy of Dermatology and Venereology (EADV) Congress
  • Oct 08, 2019: Innovation Pharmaceuticals cites recent academic literature showing host defense proteins at Cutting-Edge of Medicine for Multiple Diseases
  • Oct 08, 2019: Lilly presents on Olumiant at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
  • Oct 07, 2019: Nektar Therapeutics announces initiation of two clinical studies of novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with psoriasis and atopic dermatitis
  • Sep 27, 2019: Pfizer announces positive top-line results from second pivotal phase 3 study of investigational Oral JAK1 candidate, Abrocitinib, in patients Aged 12 and older with moderate to severe Atopic Dermatitis
  • Sep 27, 2019: Health Canada approves Dupixent™ as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis
  • Sep 17, 2019: Arena pharmaceuticals to present new preclinical atopic dermatitis data for Etrasimod at the European Society for Dermatologic Research Annual Meeting
  • Clinical Trial Profile Snapshots
Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Author
  • Contact Us
  • Source
List of Tables
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Region, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, North America, Top Countries, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019*
  • Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, G7 Countries (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, E7 Countries (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Phase, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
List of Figures
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Region (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019*
  • Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, G7 Countries (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, E7 Countries (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Phase (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
  • Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Novartis AG
  • Pfizer Inc
  • Sanofi
  • Regeneron Pharmaceuticals Inc
  • LEO Foundation
  • Astellas Pharma Inc
  • GlaxoSmithKline Plc
  • Eli Lilly and Co
  • Bayer AG
  • Galderma SA
Note: Product cover images may vary from those shown
Adroll
adroll